4-naphthalen-2-ylmethyl-piperazine-1-carboxylic acid benzo[d]isoxazol-3-ylamide | 1093210-31-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-naphthalen-2-ylmethyl-piperazine-1-carboxylic acid benzo[d]isoxazol-3-ylamide
• 英文别名: N-(1,2-benzoxazol-3-yl)-4-(naphthalen-2-ylmethyl)piperazine-1-carboxamide
• CAS: 1093210-31-1
• 化学式: C₂₃H₂₂N₄O₂
• 分子量: 386.453
• InChiKey: CTOWQBJBGFINOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE
  申请人：Apodaca Richard

  公开号：US20090062294A1

  公开（公告）日：2009-03-05

  Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

  本文描述了一些含有杂环芳基取代的哌啶基和哌嗪基脲类化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、障碍和症状的方法，例如焦虑、疼痛、炎症、睡眠障碍、进食障碍、胰岛素抵抗、糖尿病、骨质疏松和运动障碍（例如多发性硬化症）。
• [EN] HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] MODULATEURS DE L'URÉE SUBSTITUÉS HÉTÉROARYLE DAMIDE 'HYDROLASE D'ACIDES GRAS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2008153752A2

  公开（公告）日：2008-12-18

  [EN] Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).
  [FR] L'invention concerne certains composés uréiques substitués hétéroaryle de pipéridinyle et pipérazinyle qui sont utiles en tant qu'inhibiteurs de la FAAH. De tels composés peuvent être utilisés dans des compositions pharmaceutiques et dans le cadre de méthodes de traitement de maladies, de troubles et de manifestations pathologiques induites par l'amide hydrolase d'acides gras, notamment l'anxiété, la douleur, l'inflammation, les troubles de sommeil, les troubles de l'alimentation, la résistance à l'insuline, le diabète, l'ostéoporose et les troubles moteurs (comme par exemple dans la sclérose en plaques).